NASDAQ · TWST
Healthcare · Medical - Diagnostics & Research
$138.10
Up+$5.63 (+4.07%)
Updated Sep 16, 2026, 4:26 PM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
TWST closed at $138.10 after 20 trading sessions, up 18.95% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $134.04 | $138.93 | $131.54 | $138.10 | 1.29M |
| Sep 14, 2026 | $126.04 | $136.86 | $121.92 | $134.75 | 1.81M |
| Sep 11, 2026 | $127.92 | $130.00 | $125.88 | $127.22 | 1.11M |
| Sep 10, 2026 | $121.66 | $129.275 | $120.19 | $126.85 | 1.29M |
| Sep 9, 2026 | $126.51 | $130.99 | $122.52 | $125.52 | 1.84M |
| Sep 8, 2026 | $121.38 | $131.60 | $120.7075 | $128.06 | 1.81M |
| Sep 4, 2026 | $125.19 | $128.125 | $123.75 | $124.72 | 901.85K |
| Sep 3, 2026 | $132.85 | $133.95 | $127.42 | $128.71 | 1.07M |
| Sep 2, 2026 | $131.43 | $140.80 | $126.42 | $131.00 | 1.9M |
| Sep 1, 2026 | $134.94 | $138.1499 | $131.00 | $132.06 | 1.28M |
| Aug 31, 2026 | $139.99 | $140.60 | $135.00 | $139.00 | 1.89M |
| Aug 28, 2026 | $150.05 | $153.11 | $140.99 | $141.38 | 1.38M |
| Aug 27, 2026 | $149.23 | $155.44 | $148.4357 | $153.10 | 1.25M |
| Aug 26, 2026 | $148.00 | $153.9999 | $147.00 | $150.06 | 1.21M |
| Aug 25, 2026 | $145.73 | $154.96 | $141.41 | $151.42 | 2.08M |
| Aug 24, 2026 | $145.37 | $145.41 | $137.37 | $140.80 | 1.81M |
| Aug 21, 2026 | $138.43 | $145.93 | $135.05 | $145.59 | 1.8M |
| Aug 20, 2026 | $136.84 | $145.51 | $135.17 | $136.33 | 2.4M |
| Aug 19, 2026 | $128.00 | $142.84 | $127.75 | $142.39 | 3.55M |
| Aug 18, 2026 | $121.61 | $123.295 | $115.28 | $116.10 | 1.3M |
The latest Smart Investors Daily articles mentioning TWST.
TWST research
Company profile and research snapshot.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | BWS Financial | Sell | — |
| Sep 9, 2026 | UBS | Neutral | — |
| Aug 5, 2026 | Piper Sandler | Overweight | — |
| Aug 4, 2026 | Baird | Outperform | — |
| Jul 14, 2026 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 9, 2026
BWS Financial analyst Hamed Khorsand initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Sell rating and announces Price Target of $45.
Yahoo · Sep 9, 2026
SOUTH SAN FRANCISCO, Calif., September 09, 2026--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in a fireside chat at the Baird 2026 Global Healthcare Conference on Tuesday, September 15, 2026 at 1:25 pm Eastern Time in New York City.
Benzinga · Sep 9, 2026
UBS analyst Doug Schenkel initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Neutral rating and announces Price Target of $144.
Yahoo · Sep 8, 2026
Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for the “Artisan Mid Cap Fund”. The letter can be downloaded here. Global equities rebounded sharply in Q2 2026, recovering from March lows as resilient economic data, strong corporate earnings, and continued AI investment improved investor sentiment despite inflation concerns, delayed rate cuts, and […]
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TWST.
